## Unknown

From:

Melville, Margaret G

Sent:

Tuesday, December 14, 2004 7:03 PM

To:

Macfadden, Wayne; Gaddy, James; Shaw, Joan; Brecher, Martin; Schwartz, Jack A;

McCormack, Eileen; Jones, Martin AM (Seroquel); Dunscombe, Nick M

Subject:

FW: Trial 31 Position

Attachments:

FW: Quetiapine study

## Dear All,

I have spoken to Jack about Dr. Citrome's request to have information regarding Trial 31. It is likely these data will be published on the AZ Clinical Trials Register, but as I understand it SET will take the decision this week. Jack does not believe it's appropriate to wait until these data are disseminated via that route (I believe the company intends the website to be active mid 2005).

Jim gave me a quick update by voicemail (thank you Jim) that there were some outstanding stats and that the CSR is pending. He told me that you, Wayne, were the responsible physician.

At this point, I think that we should do the following:

- Wayne, put together three to four sentences describing the high-level results
- MB/Wayne get this agreed by commercial (Nick Dunscombe or Eileen McCormack)
- Provide the summary to Dr. Citrome (Jack Schwartz) before holidays commence?

If you have disagreements to this proposal please come prepared to voice them in our Thursday am teleconference from 8-9 -- Martin Jones can give you the timings.

## Best Regards.

Margaret (Meg) Melville Seroquel Acting GPD

(302) 886-2118 or 1(800) 456-3669 X 62118

mobile REDACTED

fax (302) 886-1400

margaret melville@astrazeneca

----Original Message-----

From:

Schwartz, Jack A

Sent:

Thursday, December 02, 2004 4:09 PM

To:

Jones, Martin AM (Seroquel)

Cc:

Brecher, Martin; Mueller, Karin; Melville, Margaret G; Beamish, Don G

Subject:

Trial 31 Position

## Martin,

Per my e-mail of three weeks ago, can we please add 'trial 31 position' to the agenda for the next GPT meeting. Dr. Citrome was an investigator on trial 31 and has been repeatedly asking for information on this trial. Dr. Citrome is also writing an article on atypicals and diabetes and I believe it would be in our best interest to rapidly respond to the request. I don't want to irritate him nor give him the impression that we are hiding data.

FW: Quetiapine study

Thanks, Jack